Recently, because of the emergency related to the SARS-CoV-2 pandemic, interest has arisen in the use of PDE4 inhibitors in the treatment of severe symptoms characterizing COVID-19, both for their anti-inflammatory and antiviral effect on HIV-1 replication [174]. This evidence concerns the gene PDE4A and COVID-19.